Analysis of Correlation between Mass of Muscle/Fat and Tolerability of Chemotherapy in Patients with Advanced Cancer
Not Applicable
- Conditions
- Patients with Advanced Cancer
- Registration Number
- JPRN-UMIN000037186
- Lead Sponsor
- Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who decline mass of muscle/fat
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link sarcopenia and chemotherapy resistance in advanced cancer patients?
How does body composition analysis compare to standard-of-care assessments in predicting chemotherapy tolerability?
What biomarkers correlate with muscle/fat mass in JPRN-UMIN000037186 observational cancer trial?
What adverse event management strategies improve chemotherapy tolerability in sarcopenic cancer patients?
How do metabolic therapies combined with chemotherapy affect muscle mass in advanced cancer patients?